International Stem Cell to sell Lifeline Cell Technology to ATCC for $25 million

• International Stem Cell Corporation agreed to sell Lifeline Cell Technology to American Type Culture Collection for USD 25 million, subject to closing adjustments.
• Deal transfers 100% of Lifeline’s membership interests; business supplies primary human cells, stem cells, and related research reagents.
• Cash at closing reduced by a USD 2.6 million escrow, including USD 2.5 million for indemnities and USD 100,000 for adjustments.
• Closing targeted for the third fiscal quarter of 2026, subject to customary conditions and a post-close working-capital true-up.
• Majority holders signed support agreements to vote in favor; seller faces non-solicitation limits pre-close and five-year post-close restrictions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. International Stem Cell Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-005555), on July 16, 2026, and is solely responsible for the information contained therein.